Rabies virus inactivated antigen, A

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Brand Names
Rabavert
Generic Name
Rabies virus inactivated antigen, A
DrugBank Accession Number
DB10283
Background

Rabies virus inactivated antigen, A is an inactivated virus vacine for the intramuscular injection. It is an active immunization against rabies that can be administered pre- or post-exposure to the rabies virus.

Type
Biotech
Groups
Approved, Investigational
Biologic Classification
Vaccines
Inactivated
Synonyms
  • Rabies virus strain flury lep antigen (propiolactone inactivated)
  • Rabies virus vaccine flury-lep strain

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Associated Therapies
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbataceptThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Abatacept.
AdalimumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Adalimumab.
AldesleukinThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Aldesleukin.
AlefaceptThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alefacept.
AlemtuzumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Alemtuzumab.
AltretamineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Altretamine.
AmsacrineThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Amsacrine.
AnakinraThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Anakinra.
AnifrolumabThe therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Anifrolumab.
Antilymphocyte immunoglobulin (horse)The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Antilymphocyte immunoglobulin (horse).
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
RabAvertKit; Powder, for suspension2.5 [iU]/1mLIntramuscularBavarian Nordic A/S1997-11-11Not applicableUS flag
RabAvertKit2.5 [iU]/1mLIntramuscularA-S Medication Solutions2014-07-082020-03-31US flag
RabAvertKit2.5 [iU]/1mLIntramuscularA-S Medication Solutions2016-12-19Not applicableUS flag
RabAvertKit2.5 [iU]/1mLIntramuscularGSK Vaccines GmbH2014-07-082020-03-31US flag
RabAvertKit2.5 [iU]/1mLIntramuscularGlaxoSmithKline Biologicals SA2016-12-192024-01-31US flag

Categories

ATC Codes
J06AA06 — Rabies serum
Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
FK894Q51YE
CAS number
Not Available

References

General References
Not Available
PubChem Substance
347910469
RxNav
830457

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedBasic ScienceRabies2
4CompletedBasic ScienceRabies Human1
4CompletedPreventionRabies1
4CompletedPreventionRabies Vaccine Allergy1
4CompletedTreatmentRabies1
4RecruitingPreventionCoronavirus Disease 2019 (COVID‑19) / Rabies1
4Unknown StatusHealth Services ResearchRabies1
4WithdrawnPreventionViral Disease1
3Active Not RecruitingPreventionAntibody Titer / Rabies Human1
3Active Not RecruitingPreventionMalaria1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
InjectionIntradermal; Intramuscular2.5 IU/0.5mL
KitIntramuscular2.5 [iU]/1mL
Kit; powder, for suspensionIntramuscular2.5 [iU]/1mL
Injection, powder, lyophilized, for solutionIntramuscular≥ 2.5 IU
Injection, powder, lyophilized, for solutionIntramuscular2.5 IU/ml
Injection, powder, for solutionIntramuscular2.5 iu/mL
Injection, powder, for solutionIntramuscular2.5 IU
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at November 30, 2015 21:24 / Updated at June 12, 2020 16:52